LabEx Medalis conference
28th November 2017
Strasbourg

REGISTRATION & WELCOMING COFFEE
BioFIT Exhibition hall |9:00 – 9:30 am

________________________________

Session 1: Translational research at Medalis: From lab to biotech
Moderator : Robert ZIMMER | CEO ImmuPharma

Salon  5 Rome | Nov the 28th | 9:30 – 11:00 am

ImmuPharma, a successful pioneer in academic private intimate collaboration (Sylviane MULLER, Laboratory of Immunology and Therapeutic Chemistry UPR3572 CNRS, Robert ZIMMER, CEO ImmuPharma)

From the molecular dissection of signalling receptor transmembrane domains interaction in cancer(Dominique BAGNARD, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109, Group Head) to Peptimimesis Pharma (Marjorie SIDHOUM, CEO)

From innovation in click chemistry (Alain WAGNER, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-UdS, Group Head) to Syndivia (Sasha KONIEV, CEO)

From the development of a molecular tool predicting cancer drug efficacy, (Justine Fritz, Former PhD in Dominique BAGNARD group, MN3T lab) to Adaptherapy (Bertrand LOUBATON, CEO)

________________________________

LUNCH
BioFIT Exhibition hall | 1:00 – 2:30 pm

________________________________

Session 2: Early projects, early opportunity: Find your match
Moderator: Jean-Christophe Peter (Scientific Manager, Labex Medalis)
Salon  5 Rome | Nov the 28th | 2:30 – 4:00 pm

Development of a PPI inhibitor of the CDK4/cyclin D complex for cancer treatment (Frédéric BIHEL, Laboratory of therapeutic Innovation, UMR 7200 CNRS-UdS)

Preclinical validation of the therapeutic potential of MTP-PlexA1 in demyelination disease (Fabien BINAME, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109)

Fluorospexin and Pain (Dominique BONNET, Laboratory of therapeutic Innovation, UMR 7200 CNRS-UdS, and Frédéric SIMONIN, GPCR, Pain and Inflammation, UMR 7242 CNRS-UdS)

Peptide P140 and asthma: Preclinical evaluation in relevant mouse models (Nelly FROSSARD, Laboratory of therapeutic Innovation, UMR 7200 CNRS-UdS)

Neutraligands of CXCL12 (Marcel HIBERT, Laboratory of therapeutic Innovation, UMR 7200 CNRS-UdS)

Nanostructured Carriers for Intelligent SiRNA co-delivery with anticancer drugs (Antoine KICHLER, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-UdS)

A global and rational approach to PPI modulation (Didier ROGNAN, Laboratory of therapeutic Innovation, UMR 7200 CNRS-UdS)

MicroOmics: Deciphering cancer heterogeneity at the single cell multi-omic level (Sylvain URSUEGUI, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-UdS)

________________________________

COFFEE BREAK
BioFIT Exhibition hall | 4:00 – 4:30 pm

________________________________

Session 3: Nature and nurture of an Academic drug discovery Centre
Moderator: Jean-Christophe Peter (Scientific Manager, Labex Medalis)

Salon  5 Rome | Nov the 28th | 4:30 – 6:00 pm

Round table:
> How developing a continuing research effort out of the box?
> How educating researchers at the interface of chemistry and biology?
> How involving industrial partners?
> The role of corporate sponsorship in such initiatives?

Panel:

Pierre EFTEKHARI, INOVIEM Scientifique
Serge POTIER, University of Strasbourg
Jean GAGNEUX, CiRFC Foundation
Marcel HIBERT, Faculty of Pharmacy
Stephane JENN, NOVALIX
Pascal NEUVILLE, Domain Therapeutics

________________________________

BIOPARTY
From 6.30 pm …

________________________________

Access to Medalis Conference on 28th November

Including coffee breaks and lunch

Join us and know more about our research:
1st conference on 28th November, during BioFIT 2017

Being Medalis’ attendee, you will benefit from a special rate to attend the 2nd day of Biofit (29th November)!

BioParty access on 28th November from 6.30 pm*
Join all BioFIT participants in a convivial and cozy place to begin your networking

Additional cost
€ 40 excl. VAT

Full pass to attend BioFIT event on 29th November*
A full pass provides access to:
– Partnering system (partneringONE – EBD / one-to-one meetings)
– Conferences and roundtable discussions
– Presentation sessions
– Exhibition area
– Lunch & coffee breaks

Additional cost
€ 180 excl. VAT

Visitor pass to attend BioFIT event on 29th November*
A visitor pass provides access to:
– Conferences and roundtable discussions
– Presentation sessions
– Exhibition area
– Lunch & coffee breaks

NO access to the partnering activity

Additional cost
€ 120 excl. VAT

*You could select these products during your registration process.

The Drug research center Medalis is a “Laboratory of Excellence” (Labex) created in July 2011 as part of the French program “Investments for the Future”. It is a member of Initiatives of excellence” (IDEX) in the University of Strasbourg.

Our aim is to develop innovative drugs for cancer or inflammation treatment.

Our strength:

  • A unique network of 200 researchers and postdocs coming from 11 research teams concerned with chemistry and biology whose excellency has been certified by the national “Agency for Evaluation of Research and Universities”, currently “Haut Conseil de l’Evaluation de la Recherche et de l’Enseignement Supérieur”.
  • A state of the art scientific equipments, such as platforms dedicated to virtual and microfluidic screening.
  • A stimulating environment: Medalis is based in the heart of Europe, in Strasbourg, whose research institutes are internationaly renowned for their achievements in the fields of pharmacology and biotechnologies.

Medalis researchers have access to a highly competitive research environment provided by Strasbourg University and national research Institutions like CNRS or INSERM. Moreover, Strasbourg University was awarded for the excellence of the projects supported (including Medalis) and received an Initiative of Excellence funding from French Investment for the future Program.

Our ambition: To support the development of innovative projects selected in response to our annual internal calls.  Since the creation of Medalis, a call for grant applications is launched every year.

We hope that Medalis will continue to contribute to the development of innovative drugs for treating cancer and inflammation.